CalciMedica, Inc. Files Q2 2024 10-Q
Ticker: CALC · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1534133
| Field | Detail |
|---|---|
| Company | Calcimedica, INC. (CALC) |
| Form Type | 10-Q |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting
TL;DR
**CalciMedica Q2 10-Q filed. Financials and ops update.**
AI Summary
CalciMedica, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Graybug Vision, Inc., is focused on pharmaceutical preparations. Key financial details and operational updates for the second quarter are presented in this filing.
Why It Matters
This filing provides investors with a quarterly update on CalciMedica's financial health and operational progress, crucial for understanding its current standing and future prospects in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, CalciMedica faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 20240812 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- CalciMedica, Inc. (company) — Filer of the 10-Q
- Graybug Vision, Inc. (company) — Former name of CalciMedica, Inc.
- 20240630 (date) — End of the reporting period
- 20240812 (date) — Filing date of the 10-Q
- LA JOLLA, CA (location) — Company's business and mailing address
FAQ
What is the primary business of CalciMedica, Inc.?
CalciMedica, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
When was the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing concluded on June 30, 2024.
What was CalciMedica, Inc. previously known as?
CalciMedica, Inc. was formerly known as Graybug Vision, Inc., with a name change date of March 22, 2023.
Where is CalciMedica, Inc. located?
The company's business and mailing address is located at 505 Coast Boulevard South, Suite 307, La Jolla, CA 92037.
What stock exchange is CalciMedica, Inc. listed on?
CalciMedica, Inc. is listed on NASDAQ.
Filing Stats: 4,457 words · 18 min read · ~15 pages · Grade level 17.3 · Accepted 2024-08-12 16:30:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CALC The Nasdaq Capital M
Filing Documents
- ck0001534133-20240630.htm (10-Q) — 2398KB
- ck0001534133-ex4_16.htm (EX-4.16) — 103KB
- ck0001534133-ex31_1.htm (EX-31.1) — 14KB
- ck0001534133-ex31_2.htm (EX-31.2) — 15KB
- ck0001534133-ex32_1.htm (EX-32.1) — 9KB
- ck0001534133-ex32_2.htm (EX-32.2) — 9KB
- 0000950170-24-095490.txt ( ) — 8547KB
- ck0001534133-20240630.xsd (EX-101.SCH) — 1230KB
- ck0001534133-20240630_htm.xml (XML) — 1222KB
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statement of Comprehensive Loss 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) 5 Condensed Consolidated Statements of Cash Flows 7 Notes to the Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.
Controls and Procedures
Controls and Procedures 31
—OTHER INFORMATION
PART II—OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 32 Item 1A.
Risk Factors
Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 76 Item 3. Defaults Upon Senior Securities 76 Item 4. Mine Safety Disclosures 76 Item 5. Other Information 76 Item 6. Exhibits 77
—FINANCIAL INFORMATION
PART I—FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. CALCIMEDICA, INC. Condensed Consolidated Balance Sheets (in thousands, except par value and share amounts) (Unaudited) June 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents $ 5,056 $ 5,530 Short-term investments 14,081 5,708 Prepaid expenses and other current assets 1,305 367 Total current assets 20,442 11,605 Property and equipment, net 138 167 Other assets 472 413 Total assets $ 21,052 $ 12,185 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,144 $ 1,419 Accrued clinical trial costs 829 1,141 Accrued expenses 941 1,468 Total current liabilities 3,914 4,028 Long-term liabilities Warrant liability 3,300 — Total liabilities 7,214 4,028 Commitments and contingencies (Note 9) Stockholders' equity Preferred stock, $ 0.0001 par value; 10,000,000 shares and no shares authorized at June 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023; 10,750,156 and 5,754,505 issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 1 Additional paid-in capital 163,732 154,218 Accumulated deficit ( 149,888 ) ( 146,064 ) Accumulated other comprehensive income (loss) ( 9 ) 2 Total stockholders' equity 13,838 8,157 Total liabilities and stockholders' equity $ 21,052 $ 12,185 See accompanying notes to unaudited condensed consolidated financial statements. 2 CALCIMEDICA, INC. Condensed Consolidated Statemen ts of Operations (in thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 4,1